Humacyte (NASDAQ:HUMA) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Humacyte (NASDAQ:HUMA) from a hold rating to a sell rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C. “

Other equities research analysts also recently issued research reports about the company. Oppenheimer assumed coverage on Humacyte in a research report on Thursday, September 23rd. They set an outperform rating and a $16.00 price objective for the company. Cowen assumed coverage on Humacyte in a research report on Friday, October 29th. They set an outperform rating and a $17.00 price objective for the company. Piper Sandler assumed coverage on Humacyte in a research report on Thursday, September 16th. They set an overweight rating and a $17.00 price objective for the company. Finally, BTIG Research initiated coverage on Humacyte in a research report on Wednesday, September 22nd. They set a buy rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Humacyte currently has a consensus rating of Buy and an average target price of $17.25.

HUMA opened at $5.83 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 11.49 and a quick ratio of 11.49. Humacyte has a 1-year low of $5.57 and a 1-year high of $17.45. The business has a 50 day moving average price of $9.12.

Humacyte (NASDAQ:HUMA) last released its earnings results on Friday, November 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.30). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.27 million. On average, analysts predict that Humacyte will post -1.5 EPS for the current fiscal year.

In other news, Director Brady W. Dougan sold 75,000 shares of the company’s stock in a transaction on Thursday, December 16th. The shares were sold at an average price of $9.00, for a total value of $675,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Laura E. Niklason sold 125,000 shares of the company’s stock in a transaction on Wednesday, December 15th. The stock was sold at an average price of $8.88, for a total transaction of $1,110,000.00. The disclosure for this sale can be found here. Insiders sold 300,000 shares of company stock worth $2,729,000 over the last ninety days.

A number of large investors have recently modified their holdings of the stock. LPL Financial LLC bought a new stake in Humacyte in the third quarter worth $1,331,000. CVI Holdings LLC bought a new stake in Humacyte in the third quarter worth $5,805,000. Morgan Stanley bought a new stake in Humacyte in the third quarter worth $840,000. York Capital Management Global Advisors LLC bought a new stake in Humacyte in the third quarter worth $20,590,000. Finally, Geode Capital Management LLC bought a new stake in Humacyte in the third quarter worth $359,000. Hedge funds and other institutional investors own 15.67% of the company’s stock.

About Humacyte

Alpha Healthcare Acquisition Corp. is a blank check company. It formed for the purpose of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Alpha Healthcare Acquisition Corp. is based in New York.

Read More: Understanding and Trading Breakout Stocks

Get a free copy of the Zacks research report on Humacyte (HUMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.